Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Boehringer inhalers now available at $35 a month for eligible patients Boehringer inhalers now available at $35 a month for eligible patients Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients
Results from Phase II MASH trial announced at EASL 2024 Results from Phase II MASH trial announced at EASL 2024 Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024